Aptose Biosciences (NASDAQ:APTO) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com started coverage on Aptose Biosciences in a research report on Sunday. They issued a “hold” rating for the company.

Aptose Biosciences Trading Up 27.0 %

NASDAQ APTO opened at $0.23 on Wednesday. The business’s 50 day moving average is $0.21 and its two-hundred day moving average is $0.32. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.12.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.